Literature DB >> 1370862

Brain neurotransmitter changes in human narcolepsy.

S J Kish1, M Mamelak, C Slimovitch, L M Dixon, A Lewis, K Shannak, L DiStefano, L J Chang, O Hornykiewicz.   

Abstract

We measured the concentrations of the three major monoamine neurotransmitters noradrenaline, dopamine, and serotonin, their metabolites, and receptor binding sites in autopsied brain of three patients with narcolepsy. As compared with the controls, concentrations of the noradrenaline and serotonin metabolites MHPG and 5-HIAA, respectively, were markedly elevated in cerebral cortical subdivisions of the narcolepsy patients together with a trend for above-normal neurotransmitter/metabolite "turnover" ratio. A moderately reduced number of alpha 1-adrenoceptors, as judged by the reduced levels of 3H-prazosin binding, was observed in cerebral cortex of two of the three patients with narcolepsy. Mean striatal levels of dopamine and its metabolite homovanillic acid were normal, whereas the concentration of dopamine's second metabolite, dihydroxyphenylacetic acid, was markedly reduced by 50% or greater. This was accompanied by a marked increase (+125%) in mean 3H-spiperone binding to the D2 dopamine receptor in both caudate and putamen; in contrast, the levels of 3H-SCH 23390 binding to the striatal D1 dopamine receptor were in the normal range. Our data provide evidence for altered brain monoaminergic neurotransmitter function in human narcolepsy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370862     DOI: 10.1212/wnl.42.1.229

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model.

Authors:  M Tafti; S Nishino; M S Aldrich; W Liao; W C Dement; E Mignot
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

Review 2.  Positron emission tomography studies of sleep and sleep disorders.

Authors:  P Maquet
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

3.  Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy.

Authors:  T M Sinnwell; K Sivakumar; S Soueidan; C Jay; J A Frank; A C McLaughlin; M C Dalakas
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

4.  Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT.

Authors:  Tomohisa Mori; Naoki Uzawa; Yoshiyuki Iwase; Daiki Masukawa; Mahardian Rahmadi; Shigeto Hirayama; Mayuna Hokazono; Kimio Higashiyama; Seiji Shioda; Tsutomu Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2016-04-11       Impact factor: 4.530

Review 5.  Neuroimaging insights into the pathophysiology of sleep disorders.

Authors:  Martin Desseilles; Thanh Dang-Vu; Manuel Schabus; Virginie Sterpenich; Pierre Maquet; Sophie Schwartz
Journal:  Sleep       Date:  2008-06       Impact factor: 5.849

6.  Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine.

Authors:  M S Reid; M Tafti; S Nishino; R Sampathkumaran; J M Siegel; E Mignot
Journal:  Brain Res       Date:  1996-09-09       Impact factor: 3.610

7.  Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain.

Authors:  Julia Lindberg; Peter Saetre; Seiji Nishino; Emmanuel Mignot; Elena Jazin
Journal:  BMC Neurosci       Date:  2007-05-23       Impact factor: 3.288

8.  Sleep, Narcolepsy, and Sodium Oxybate.

Authors:  Mortimer Mamelak
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.